Growth Metrics

West Pharmaceutical Services (WST) Depreciation & Amortization (CF) (2016 - 2026)

West Pharmaceutical Services has reported Depreciation & Amortization (CF) over the past 18 years, most recently at $44.6 million for Q1 2026.

  • Quarterly Depreciation & Amortization (CF) rose 14.07% to $44.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $174.1 million through Mar 2026, up 11.46% year-over-year, with the annual reading at $168.6 million for FY2025, 11.07% up from the prior year.
  • Depreciation & Amortization (CF) was $44.6 million for Q1 2026 at West Pharmaceutical Services, down from $46.4 million in the prior quarter.
  • Over five years, Depreciation & Amortization (CF) peaked at $46.4 million in Q4 2025 and troughed at $28.7 million in Q1 2022.
  • The 5-year median for Depreciation & Amortization (CF) is $34.8 million (2023), against an average of $36.2 million.
  • Biggest five-year swings in Depreciation & Amortization (CF): fell 6.81% in 2022 and later increased 20.42% in 2023.
  • Tracing WST's Depreciation & Amortization (CF) over 5 years: stood at $30.1 million in 2022, then rose by 14.95% to $34.6 million in 2023, then rose by 15.03% to $39.8 million in 2024, then increased by 16.58% to $46.4 million in 2025, then decreased by 3.88% to $44.6 million in 2026.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $44.6 million, $46.4 million, and $42.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.